| ²é¿´: 344 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
Íõ¹ðÀ¼Òø³æ (СÓÐÃûÆø)
|
[½»Á÷]
ÇóÖúRiociguat Õâ¸öÐÂÒ©µÄÖÐÎÄÃû×Ö£¿Íò·Ö¸Ðл
|
||
|
ÏÂÃæÊÇÎÄÏ×Àï¶ÔËüµÄÃèÊö£¬Íò·Ö¸Ðл (BAY 63- 2521) is a first-in-class drug developed by Bayer Schering Pharma as an oral PH therapy. |
» ²ÂÄãϲ»¶
¿¼ÑÐÉúÎïѧ¿¼AÇø211£¬³õÊÔ322£¬¿ÆÄ¿Éú»¯ºÍÉúÎï×ۺϣ¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸0817»¯Ñ§¹¤³ÌÓë¼¼Êõ£¬Çóµ÷¼Á
ÒѾÓÐ28È˻ظ´
085600£¬320·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
µ÷¼Á
ÒѾÓÐ6È˻ظ´
333Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ó¢Ò»Êý¶þÉúÎïÐÅϢѧ287·Ö£¬±¾¿ÆÉúÎï¿ÆÑ§£¬Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
291Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸»¦9£¬ÇóÉúÎïѧµ÷¼Á£¬326·Ö
ÒѾÓÐ4È˻ظ´
0856Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
hy52x
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 5363.3
- É¢½ð: 34
- ºì»¨: 1
- Ìû×Ó: 309
- ÔÚÏß: 417Сʱ
- ³æºÅ: 894154
- ×¢²á: 2009-11-05
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×Ӻϳɻ¯Ñ§
¡ï ¡ï ¡ï ¡ï
Íõ¹ðÀ¼(½ð±Ò+4,VIP+0):лл£¬ÐÁ¿àÁË 11-10 20:48
Íõ¹ðÀ¼(½ð±Ò+4,VIP+0):лл£¬ÐÁ¿àÁË 11-10 20:48
|
(BAY 63-2521)ÊÇÓÉBayer Schering Pharma Ëù·¢Õ¹µÄµÚÒ»Àà¿ÚÇ»pHÖÎÁÆÒ©Îï (BAY 63-2521)Õâ¾ÍÊǰݶú¹«Ë¾µÄÒ»¸öÒ©Ãû£¬Ã»±ØÒª·Òë°É [ Last edited by hy52x on 2009-11-9 at 20:39 ] |
2Â¥2009-11-09 20:35:22
sugar-tang
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 96.6
- É¢½ð: 1076
- ºì»¨: 1
- Ìû×Ó: 284
- ÔÚÏß: 80.9Сʱ
- ³æºÅ: 843493
- ×¢²á: 2009-09-08
- רҵ: ÉúÀíÉú̬ѧ
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Íõ¹ðÀ¼(½ð±Ò+6,VIP+0):ÐÁ¿àÁË£¬ºÜÓÐÓã¬Ð»Ð» 11-10 20:49
Íõ¹ðÀ¼(½ð±Ò+6,VIP+0):ÐÁ¿àÁË£¬ºÜÓÐÓã¬Ð»Ð» 11-10 20:49
|
ά»ùÉϲ鵽µÄ£¬Riociguat (BAY 63-2521) is an experimental drug for the treatment of pulmonary arterial hypertension. As of March 2009, it is undergoing Phase III clinical trials. RiociguatÊÇÒ»ÖÖʵÑéÐÔÒ©ÎÓÃÓÚÖÎÁƷζ¯Âö¸ßѪѹ¡£½«ÓÚ2009Äê3Ô½øÐÐÁÙ´²ÊÔÑé¡£ÎÒ¾õµÃÕâÖÖÒ©¼ÈÈ»»¹Ö»ÊÇÔÚÁÙ´²ÊÔÑé½×¶Î¾Í²»»áÓÐÖÐÎÄÃûÄØ£¡ Ï£ÍûÒÔÉÏ×ÊÁ϶ÔÄãÓаïÖú ![]() [ Last edited by sugar-tang on 2009-11-9 at 20:48 ] |

3Â¥2009-11-09 20:46:40














»Ø¸´´ËÂ¥
